New and emerging contraceptives: a state-of-the-art review

被引:25
作者
Bahamondes, Luis [1 ,2 ]
Valeria Bahamondes, M. [1 ,2 ]
机构
[1] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynaecol, Human Reprod Unit, Campinas, SP, Brazil
[2] Natl Inst Hormones & Womens Hlth, Campinas, SP, Brazil
来源
INTERNATIONAL JOURNAL OF WOMENS HEALTH | 2014年 / 6卷
关键词
emerging contraceptives; patch; vaginal ring; intrauterine devices; spray; emergency contraceptives;
D O I
10.2147/IJWH.S46811
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: The first hormonal contraceptive was introduced onto the market in several countries 50 years ago; however, the portfolio of contraceptive methods remains restricted with regards to their steroid composition, their cost, and their ability to satisfy the requirements of millions of women/couples in accordance with their different reproductive intentions, behaviors, cultures, and settings. Methods: A literature review was conducted using Medline, Embase, and Current Contents databases, up to September 1, 2013 to identify publications reporting new contraceptives in development using combinations of the search terms: contraception, contraceptives, oral contraceptives, patch, vaginal ring, implants, intrauterine contraceptives, and emergency contraception (EC). Also, several experts in the field were also consulted to document ongoing projects on contraception development. Additionally, the Clinicaltrial. gov website was searched for ongoing studies on existing contraceptive methods and new and emerging female contraceptives developed over the past 5 years. Information was also obtained from the pharmaceutical industry. Results: Early sexual debut and late menopause means that women may require contraception for up to 30 years. Although oral, injectable, vaginal, transdermal, subdermal, and intrauterine contraceptives are already available, new contraceptives have been developed in an attempt to reduce side effects and avoid early discontinuation, and to fulfill women's different requirements. Research efforts are focused on replacing ethinyl-estradiol with natural estradiol to reduce thrombotic events. In addition, new, less androgenic progestins are being introduced and selective progesterone receptor modulators and new delivery systems are being used. In addition, research is being conducted into methods that offer dual protection (contraception and protection against human immunodeficiency virus transmission), and contraceptives for use " on demand." Studies are also investigating non-hormonal contraceptive methods that have additional, non-contraceptive benefits. Conclusion: The most pressing need worldwide is, first, that the highly effective contraceptive methods already available should be affordable to most of the population and also that these methods should fulfill the needs of women of different ages and with different reproductive requirements. The development of new contraceptive methods should also take advantage of the knowledge obtained over the past 30 years on gamete physiology and gamete interaction to avoid the use of steroid compounds.
引用
收藏
页码:221 / 234
页数:14
相关论文
共 117 条
  • [1] Pharmacokinetics of a contraceptive patch (Evra™/Ortho Evra™) containing norelgestromin and ethinyloestradiol at four application sites
    Abrams, LS
    Skee, DM
    Natarajan, J
    Wong, FA
    Anderson, GD
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (02) : 141 - 146
  • [2] Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants
    Abrams, LS
    Skee, DA
    Natarajan, J
    Wong, FA
    Lasseter, KC
    [J]. CONTRACEPTION, 2001, 64 (05) : 287 - 294
  • [3] Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra™/Evra™) under conditions of heat, humidity, and exercise
    Abrams, LS
    Skee, DM
    Natarajan, J
    Wong, FA
    Leese, PT
    Creasy, GW
    Shangold, MM
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (12) : 1301 - 1309
  • [4] Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 μg of ethinyl estradiol and 3 mg of drospirenone
    Ahrendt, Hans-Joachim
    Nisand, Israel
    Bastianelli, Carlo
    Gomez, Maria Angeles
    Gemzell-Danielsson, Kristina
    Urdl, Wolfgang
    Karskov, Birgit
    Oeyen, Luc
    Bitzer, Johannes
    Page, Geert
    Milsom, Ian
    [J]. CONTRACEPTION, 2006, 74 (06) : 451 - 457
  • [5] Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel
    Ahrendt, Hans-Joachim
    Makalova, Dagmar
    Parke, Susanne
    Mellinger, Uwe
    Mansour, Diana
    [J]. CONTRACEPTION, 2009, 80 (05) : 436 - 444
  • [6] [Anonymous], 2009, CYCL WEBP INT
  • [7] ASTEDT B, 1979, BRIT J OBSTET GYNAEC, V86, P732
  • [8] CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914
    Attardi, BJ
    Burgenson, J
    Hild, SA
    Reel, JR
    Blye, RP
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2002, 188 (1-2) : 111 - 123
  • [9] Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive - A randomized controlled trial
    Audet, MC
    Moreau, M
    Koltun, WD
    Waldbaum, AS
    Shangold, G
    Fisher, AC
    Creasy, GW
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (18): : 2347 - 2354
  • [10] Bahamondes M Valeria, 2011, Contraception, V84, pe11, DOI 10.1016/j.contraception.2011.05.012